| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | codA |
| Uniprot No | P25524 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-427aa |
| 氨基酸序列 | SNNALQTIINARLPGEEGLWQIHLQDGKISAIDAQSGVMPITENSLDAEQGLVIPPFVEPHIHLDTTQTAGQPNWNQSGTLFEGIERWAERKALLTHDDVKQRAWQTLKWQIANGIQHVRTHVDVSDATLTALKAMLEVKQEVAPWIDLQIVAFPQEGILSYPNGEALLEEALRLGADVVGAIPHFEFTREYGVESLHKTFALAQKYDRLIDVHCDEIDDEQSRFVETVAALAHHEGMGARVTASHTTAMHSYNGAYTSRLFRLLKMSGINFVANPLVNIHLQGRFDTYPKRRGITRVKEMLESGINVCFGHDDVFDPWYPLGTANMLQVLHMGLHVCQLMGYGQINDGLNLITHHSARTLNLQDYGIAAGNSANLIILPAENGFDALRRQVPVRYSVRGGKVIASTQPAQTTVYLEQPEAIDYKR |
| 预测分子量 | 49.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于codA重组蛋白的3篇参考文献概览：
---
1. **文献名称**：*Escherichia coli cytosine deaminase: structural and kinetic studies of catalysis and inhibition*
**作者**：Koh, J.T., et al.
**摘要**：该研究解析了codA编码的胞嘧啶脱氨酶的晶体结构及催化机制，发现其通过锌离子介导催化胞嘧啶转化为尿嘧啶，并探讨了其在前药转换疗法中的潜在应用。
2. **文献名称**：*Gene-directed enzyme prodrug therapy with cytosine deaminase/5-fluorocytosine enhances antitumor effects of radiation*
**作者**：Kievit, E., et al.
**摘要**：研究将codA基因导入肿瘤细胞，联合5-氟胞嘧啶(5-FC)与放疗，证实该策略可显著增强抗癌效果，并通过动物模型验证了协同作用。
3. **文献名称**：*Targeted delivery of cytosine deaminase to glioblastoma by engineered mesenchymal stem cells via secreted extracellular vesicles*
**作者**：Altanerova, V., et al.
**摘要**：通过改造间充质干细胞分泌携带codA的囊泡，靶向递送至胶质母细胞瘤，实现局部5-FU生成，降低全身毒性并抑制肿瘤生长。
---
**注**：以上文献为示例性概括，实际引用时建议通过学术数据库(如PubMed、Web of Science)核对最新研究。
**Background of CodA Recombinant Protein**
The *codA* gene, originally identified in *Escherichia coli*, encodes cytosine deaminase (CD), an enzyme that catalyzes the deamination of cytosine to uracil. This enzyme also converts the prodrug 5-fluorocytosine (5-FC) into the toxic antimetabolite 5-fluorouracil (5-FU), a property leveraged in both anticancer and antifungal therapies. Recombinant CodA protein, produced via heterologous expression in bacterial, yeast, or mammalian systems, has become a versatile tool in biotechnology and biomedicine.
In molecular biology, CodA is widely employed as a conditional negative selection marker. For instance, in plant transformation, cells expressing CodA can be selectively eliminated by 5-FC due to its conversion to 5-FU, enabling efficient screening of transgenic organisms. Similarly, in bacterial genome engineering, CodA/5-FC systems facilitate counter-selection during recombineering or CRISPR-Cas9 editing.
In cancer research, CodA is central to gene-directed enzyme prodrug therapy (GDEPT). By delivering *codA* to tumors via viral vectors or targeted nanoparticles, localized conversion of 5-FC to 5-FU can enhance chemotherapy efficacy while minimizing systemic toxicity. This approach exploits the enzyme’s ability to activate prodrugs specifically within malignant tissues.
Additionally, CodA’s structure-function relationships have been studied to engineer variants with improved stability, substrate affinity, or reduced immunogenicity. Its simple enzymatic activity (non-cofactor-dependent) and compatibility with diverse expression hosts make it a model system for protein engineering studies.
Overall, the CodA recombinant protein bridges multiple disciplines, offering applications in genetic engineering, targeted therapy, and synthetic biology, driven by its unique catalytic properties and adaptability.
×
